Pharmaceutical - Research & Development

Research and Development

Tokyo New Drug Research Laboratories and Fuji Research Laboratories are the core centers for our research and development activities in Japan.
At the Tokyo New Drug Research Laboratories, we conduct extensive research activities, including searching for new materials and product opportunities and their biological screening, molecular design, and preclinical studies such as biokinetic studies of medicine.
The Fuji Research Laboratories have two research divisions: 1) safety research and drug formulation research, where researchers are dedicated to product safety testing, and 2) research on drug delivery systems (DDS) for efficiently delivering drugs to the target site, development of new dosage forms, development of over-the-counter (OTC) drugs, and production of investigational agents.
We are working on research and development of our global products mainly in the United States, Europe and Asia.

Target Areas of R&D

Lifestyle-related diseases

Immunity Inflammation

Sensory organ diseases

Pipeline

As of August 31, 2026

Development Code	Nonproprietary Name	Classification	Target Disease/ Condition	Development Phase
K-924	Pitavastatin/ Ezetimibe	HMG-CoA reductase inhibitor/ NPC1L1 inhibitor	Dyslipidemia	Filed (Thailand) Phase Ⅲ (Europe)
K-877	Pemafibrate	Selective PPARα modulator	Dyslipidemia	Filed (Hong Kong, Philippines, Vietnam,Thailand, Singapore)
K-808	Pemafibrate	Selective PPARα modulator	Primary biliary cholangitis (PBC)	Phase Ⅱ (Japan, US)
K-001	Pemafibrate/ Tofogliflozin	Selective PPARα modulator/ SGLT2 inhibitor	Metabolic dysfunction associated steatohepatitis (MASH)	Phase Ⅱ (Japan, US, Europe)
K-321	Ripasudil	Rho kinase inhibitor	Fuchs endothelial corneal dystrophy(FECD)	Phase Ⅲ (US, Europe)
K-911	Bimatoprost grenod (JAN application under review)	Prostanoid FP receptor agonist and Nitric oxide donor	Glaucoma and ocular hypertension	Filed (US) Phase Ⅲ (Japan)
KI-362	Preloaded posterior chamber IOL	Visual correction of the aphakic eye	Cataracts	Phase Ⅲ (US)

＜Notes＞

· Only a product in Clinical Stage is listed. This list does not include all of the products.
· A product in Clinical Stage is defined as a product for which a regulatory procedure has been made for initiation of a first clinical trial (i.e. Investigational New Drug application in US, Clinical Trial Application in Europe, Clinical Trial Notification in Japan, or a similar process in other regions) and a decision for discontinuation/suspension of clinical development activities has not been made or regulatory approval has not been obtained in any regions where approval is anticipated.
· Not all of the developing countries/regions are listed. In addition, countries where regulatory application for marketing authorization (e.g. New Drug Application in US) has been filed with an approval yet to be granted, are also listed.
· This list also includes a product in Clinical Stage for new indication(s) even if it has been already approved for different indication(s).